Shares of PLx Pharma Inc (NASDAQ:PLXP) have received an average broker rating score of 2.00 (Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating.
Analysts have set a 12 month consensus price objective of $12.00 for the company and are expecting that the company will post ($0.51) EPS for the current quarter, according to Zacks. Zacks has also given PLx Pharma an industry rank of 169 out of 265 based on the ratings given to its competitors.
A number of analysts have recently commented on PLXP shares. Zacks Investment Research cut shares of PLx Pharma from a “buy” rating to a “sell” rating in a report on Tuesday, October 3rd. ValuEngine upgraded shares of PLx Pharma from a “strong sell” rating to a “sell” rating in a report on Monday, December 4th.
A hedge fund recently bought a new stake in PLx Pharma stock. Harel Insurance Investments & Financial Services Ltd. purchased a new position in PLx Pharma Inc (NASDAQ:PLXP) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 250,000 shares of the biotechnology company’s stock, valued at approximately $145,000. Harel Insurance Investments & Financial Services Ltd. owned about 2.88% of PLx Pharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.87% of the company’s stock.
About PLx Pharma
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.